New hope for elderly blood cancer patients: experimental transplant prep shows promise
NCT ID NCT07500753
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new combination of drugs (cladribine, lisaftoclax, busulfan, and others) given before a stem cell transplant in 30 older adults (age 50+) with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes. The goal is to see if this approach can reduce side effects, lower relapse rates, and improve survival compared to standard treatments. Participants will be followed for at least two years to track outcomes like relapse-free survival and engraftment success.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cladribine, lisaftoclax, busulfan, and other chemotherapy drugs
- What this could lead to
- If successful, this could offer a more tolerable and effective transplant preparation for older adults with relapsed or refractory AML/MDS, potentially improving long-term survival.
- What could go wrong
- This is a small, early-phase study with only 30 participants, so results may not apply broadly. The drug combo carries risks like infection, organ damage, and graft-versus-host disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MDS (MYELODYSPLASTIC SYNDROME) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215006, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill boost the power of an existing leukemia treatment?
- Personalized dosing may improve stem cell transplant survival in blood cancer patients
- Could bone marrow from deceased donors cure blood cancers?
- Single-Dose gene therapy aims to reprogram immune cells against tough leukemia
- New pill targets rare gene mutation in Hard-to-Treat blood cancers
- New blood test may predict cancer relapse after transplant